Longeveron (LGVN) Total Debt (2021 - 2023)

Longeveron (LGVN) recorded quarterly Total Debt of $586000.0 in Q3 2023, up 1.38% quarter-over-quarter from $578000.0 in Q2 2023.

Longeveron (LGVN) Total Debt (2021 - 2023) Analysis & Trends

Longeveron's Total Debt history runs 3 years deep, the most recent figure standing at $586000.0 for Q3 2023.

  • In Q3 2023, Total Debt changed N/A year-over-year to $586000.0; the TTM figure through Sep 2023 stood at $586000.0 (changed N/A YoY), while the FY2022 annual figure was $564000.0, up 5.03% from the prior year.
  • Total Debt was $586000.0 for Q3 2023 at Longeveron, up from $578000.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $586000.0 in Q3 2023 to a low of $537000.0 in Q4 2021.
  • Historically, Total Debt has averaged $567200.0 across 3 years, with a median of $571000.0 in 2023.
  • Biggest YoY gain for Total Debt was 5.03% in 2022; the steepest drop was 5.03% in 2022.
  • A 3-year view of Total Debt shows it stood at $537000.0 in 2021, then advanced by 5.03% to $564000.0 in 2022, then advanced by 3.9% to $586000.0 in 2023.
  • The last three Total Debt figures came in at $586000.0 (Q3 2023), $578000.0 (Q2 2023), and $571000.0 (Q1 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 319.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Longeveron 20.35 Bn 20.33 Bn 264,000.00 -

Historic Data

Download Data
DateValue
Sep 30, 2023 586,000.00
Jun 30, 2023 578,000.00
Mar 31, 2023 571,000.00
Dec 31, 2022 564,000.00
Dec 31, 2021 537,000.00